Noridian revises MolDX minimal residual disease article A58454 (R20): two Q4 codes added, RaDaR added
Published November 8, 2026 · Coverage November 1–7, 2026, Pacific · Lower priority
Noridian posted revision 20 of billing and coding article A58454 on November 5, 2026 for JE Part A and Part B. The revision adds codes 0688U and 0689U to Group 1 as part of the 2026 Q4 code update, effective October 1, 2026, and adds the RaDaR test to the test-specific indications after a completed technical assessment, effective April 9, 2026.
Background
A58454 is a billing and coding article that complements the Local Coverage Determination (LCD) MolDX: Minimal Residual Disease Testing for Cancer, L38814; billing and coding articles provide guidance for the related LCD and assist providers in submitting correct claims for payment. The related LCD defines a minimal residual disease (MRD) test as a service that may include multiple components and/or multiple timepoints (serial assays).
Who this affects
Laboratories and other providers that bill minimal residual disease testing for solid tumor cancers under Noridian JE Part A or Part B (inference from the article's subject and contract numbers).
Why it matters
Inference: a lab that bills these tests may want to confirm claims since 2026-10-01 for the new codes, and since 2026-04-09 for RaDaR, line up with the revised article.
Recommended action
- Laboratory billing: check any MRD claims against the R20 article.
Scope and timing
- Authority status
- Effective
- Responsible owner
- Revenue Cycle
- Publication date
- 2026-11-05 (Noridian JE Part A and Part B notices)
- Effective date
- Multiple: 2026-10-01 for codes 0688U and 0689U; 2026-04-09 for the RaDaR addition
- Other dates
- Medicare Coverage Database (MCD) revision history date 10/01/2026
Not established
The tests that 0688U and 0689U describe were not identified from the retained files.
Sources
Complete edition and supplemental material
This article in the complete report →
Executive triage, source-coverage limitations, context and forward horizons remain in the complete report.
Read the entire Medicare & Medicaid Sweep report →